Isovorin

Levoleucovorin, the active ingredient in Isovorin, is a folinic acid analog presented as a sterile injectable solution for intramuscular and intravenous use. It is employed to enhance the efficacy of 5‑fluorouracil‑based chemotherapy and to rescue normal cells after high‑dose methotrexate treatment in adult patients with solid tumours.

GNH USA supplies Isovorin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Isovorin is used as an adjunct in chemotherapy regimens that involve fluoropyrimidines and high‑dose methotrexate. - 5‑Fluorouracil‑based chemotherapy: enhances the cytotoxic effect of 5‑FU, improving tumour response. - High‑dose methotrexate therapy: rescues normal cells from folate deficiency, reducing toxicity. - Colorectal cancer treatment protocols: supports standard regimens by stabilizing drug‑target interaction.

Levoleucovorin may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Rash - Fever - Headache

Serious or Rare Side Effects: - Anaphylaxis - Severe hypersensitivity reactions - Renal impairment - Cardiac arrhythmia - Neutropenia - Thrombocytopenia

When using Isovorin, several precautionary measures should be observed to ensure patient safety. - Assess renal function: evaluate creatinine clearance before administration. - Monitor complete blood count: watch for cytopenias during therapy. - Check for folate deficiency: consider baseline folate levels in at‑risk patients. - Avoid use in patients with known hypersensitivity to folinic acid analogues. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Levoleucovorin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Antifolate agents (e.g., pemetrexed): may antagonize levoleucovorin’s rescue effect. - High‑dose methotrexate without appropriate timing: can increase toxicity if not properly sequenced. - Live vaccines: potential alteration of immune response.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal clearance of levoleucovorin. - Loop diuretics: increase risk of electrolyte disturbances. - Vitamin supplements containing folic acid: may diminish the intended pharmacodynamic effect.